Immunization

An analysis found all-cause pneumonia Black, lower-income, and medically at-risk children still face substantially higher rates of hospitalization.

A cross-sectional survey links chronic fatigue, cognitive impairment, and menstrual irregularity to COVID-19 vaccination, with rates differing by brand.

Thomas Lew, MD, ABIM, Molly O’Shea, MD, FAAP, and Jesse Goodman, MD, MPH, discuss vaccine policy changes and their impact on measles outbreaks.

A population-level analysis finds that age, comorbidity burden, and long-term care residence continue to drive severe outcomes.

Data show adults who received the recombinant shingles vaccine had a lower cardiovascular burden than those who received the discontinued live vaccine.

The 4 key organizations regularly focusing on respiratory virus season released updated vaccine recommendations for 2026-2027.

As data reframes vaccines as a lifelong tool, pharmacists are becoming the access point that keeps patients up to date at every stage of life.

Independent pharmacist Tom DePietro explains how shifting vaccine policies, ACIP changes, and patient confusion are reshaping immunization at the pharmacy counter.

Live attenuated influenza vaccine increased pneumococcal density in vaccinated children, raising odds of pneumococcal infection among household contacts.

The federal government is actively looking to enhance its evolving approach toward US childhood vaccine recommendations.

Pfizer and BioNTech, Moderna, Sanofi, and Takeda received FDA approval for updated 2026-2027 COVID-19 vaccines reformulated to target the XFG variant.

New consensus confirms that chronic obstructive pulmonary disease, asthma, bronchiectasis, and lung cancer are indications for pneumococcal vaccination.

Focusing on serotype distribution, resistance trends, and vaccination impact, researchers analyze invasive pneumococcal disease burden.

A tool now tracks measles, meningitis, and whooping cough at the state and substate level, giving pharmacists a new resource to identify local outbreaks.

Giving 15-valent pneumococcal conjugate vaccine alongside acellular DTaP did not compromise antibody responses to either vaccine.

Through the scope of Nigerian pharmacists and their vaccination rates, researchers assessed strategies for advancing public health.

Among COVID-19 vaccine recipients, researchers assess the safety and efficacy of the 2023-24 protein-based and mRNA COVID-19 vaccines.

Pharmacists navigate ACIP changes, legal battles, and shifting vaccine schedules reshaping US immunization policy and respiratory season planning.

Across 3 survey periods spanning 2017 to 2023, researchers assess various institutions’ knowledge of pneumococcal vaccination.

A cohort of Black and white Americans was asked about medical racism, misinformation, COVID-19 vaccine safety, and more.

A year of ACIP turnover, schedule changes, and lawsuits has fractured US vaccine guidance—and tied pharmacists' scope and billing to a moving target.

The academy's updated influenza guidance arrives days after a White House executive order narrowed the recommended childhood vaccine schedule.

The White House and the American Academy of Pediatrics leave pharmacists navigating 2 competing sets of vaccine guidance for the upcoming season.

A decades-long research effort in mRNA-produced licensed vaccines targets influenza, respiratory syncytial virus, cytomegalovirus, HIV, and cancer.

Researchers aimed to better understand the prominence of vaccine failures and breakthrough infections of pediatric pneumoccoal immunization.